22785-43-9

Usage

Uses

Used in Pharmaceutical Industry:
S-3-N-Cbz-amino-2,6-Dioxo-piperidine is used as a key intermediate in the synthesis of Lenalidomide, an important drug used for the treatment of multiple myeloma and myelodysplastic syndromes. Its unique structure allows for the formation of essential chemical bonds and reactions that are necessary for the production of Lenalidomide, making it a vital component in the pharmaceutical industry.
Used in Oncology Research:
As a precursor to Lenalidomide, S-3-N-Cbz-amino-2,6-Dioxo-piperidine contributes to the development of therapeutic agents that target various types of cancer. Lenalidomide, the final product, has been shown to have immunomodulatory and anti-angiogenic properties, making it effective against multiple myeloma and other malignancies. The compound's role in the synthesis of such a potent drug highlights its importance in oncology research and drug development.

InChI:InChI=1/C13H14N2O4/c16-11-7-6-10(12(17)15-11)14-13(18)19-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,18)(H,15,16,17)/t10-/m0/s1

Upstream product

• 67-56-1 methanol 
• 2650-64-8 Cbz-L-Gln 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 56-85-9 L-glutamine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 202271-89-4 (R)-(+)-4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3-dione 
• 202271-89-4 (S)-(-)-4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3-dione 
• 19171-18-7 4-NT 
• 1314881-81-6 padanamide B 
• 1426657-05-7 C₃₇H₆₀N₆O₉Si 
• 492-87-5 N-[(3S)-2,6-dioxo-1-(2-phenylethyl)-3-piperidinyl]-(2S)-2-methylbutanamide 
• 1356018-29-5 (S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methyl-N-(2-oxo-2-(4-oxo-4-(pyren-1-ylmethylamino)butylamino)ethyl)butanamide 
• 1356018-27-3 4-(2-((S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methylbutanamido)acetamido)butanoic acid 
• 1356018-26-2 benzyl 4-(2-((S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methylbutanamido)acetamido)butanoate 
• 1356018-37-5 tert-butyl (2S,3S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-3-methyl-1-oxopentan-2-ylcarbamate 
• 1356018-36-4 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate 
• 1356018-35-3 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-4-methyl-1-oxopentan-2-ylcarbamate 
• 1356018-34-2 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1356018-33-1 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-1-oxopropan-2-ylcarbamate 

Relevant academic research and scientific papers

Preparation method of deuterated intermediate

The present invention provides a preparation method of a deuterated intermediate. The deuterated intermediate has a structure shown by a formula I; the preparation method comprises the following steps: amino groups in a raw material A and an aldehyde grou

Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER

Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

Total synthesis of padanamides A and B

The first total syntheses of padanamides A and B have been achieved, unambiguously confirming their structures. The Royal Society of Chemistry.

Synthesis of (-)-julocrotine and a diversity oriented Ugi-approach to analogues and probes

An improved total synthesis of (-)-julocrotine in three steps from Cbz-glutamine, in 51% overall yield, is presented. To demonstrate the potential of the heterocyclic moiety for diversity oriented synthesis, a series of (-)-julocrotine analogues was synthesized by employing the heterocyclic precursor as an amino input in Ugi four-component reactions (Ugi-4CR) [1].

5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS

Taught are derivatives of 5H-thioeno(3,4-c)pyrrole-4,6-dione, their organic, and inorganic salts, methods of synthesis of these derivatives, and their application as active pharmaceutical-ingredients useful as inhibitors of TNFα, the derivative being represented by the general formula (I): in which R1 represents H, C1-6alkyl, OR4, OC(O)R5, NO2, NHC(O)R6, or NR7R8; R2 represents H, a halogen, or C1-6alkyl; R3 represents H, methyl, isopropyl, allyl, benzyl, CH2CO2(C1-6alkyl), or CH2(CH2)nR9; R4, R5, R6, R7, and R8 each independently and at each occurrence represents H, or C1-6alkyl; R9 represents H, C1-6alkyl, OH, OC1-6alkyl, NH2, NHC1-6alkyl, N(C1-6alkyl)2, or CO2(C1-6alkyl); and n represents 1, 2, 3, or 4.

NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.

An expeditious synthesis of cyclic imides

Trifluoroacetamide was reacted with diacids in the presence of N-ethyl- N-dimethylaminopropylcarbodiimide and of 1-hydroxybenzotriazole to afford cyclic imides of different ring size, providing a single step asymmetric synthesis of thalidomide.

'BOP' as a reagent for mild and efficient preparation of esters

A simple procedure for preparation of esters under mild conditions employing the BOP reagent is reported. Acid and base labile protecting groups commonly used with amino acids e.g. t-butyl, Fmoc etc., are well tolerated under these conditions. The mechani

Circular Dichroism Spectra and Molecular Geometry of Six-Membered Ring Anhydrides and Imides

Several six-membered ring anhydrides and imides of known absolute configuration have been synthesized and their c.d. spectra measured.It has been established that the shape of the c.d. curves of anhydrides is generally similar to those of the correspondin